Pilocarpine hydrochloride
|
Treatment of dry mouth in patients with Sjögren’s syndrome
|
Cholinergic agonist
|
1992
|
1998
|
RCT
|
256
|
mean 57 years (24 – 85)
|
12 weeks
|
Global improvement of dry mouth
|
[26]
|
RCT
|
373
|
mean 55 years (21 – 84)
|
12 weeks
|
Global improvement of dry mouth
|
Etanercept
|
Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs
|
Tumor necrosis factor-alpha inhibitor
|
1998
|
1999
|
RCT
|
69
|
2 – 17 years
|
7 months
|
JIA definition of improvement criteria
|
[10]
|
Dexamethasone (intravitreal implant)
|
Treatment of non-infectious uveitis affecting the posterior segment of the eye
|
Glucocorticoid
|
1998
|
2010
|
RCT
|
153
|
n/a
|
8 weeks
|
Vitreous haze score and 3-line improvement from baseline in best corrected visual acuity
|
[27]
|
Fluocinolone acetonide (intravitreal implant)
|
Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye
|
Glucocorticoid
|
2000
|
2005
|
RCT
|
108
|
n/a
|
3 years
|
Rate of recurrence of uveitis affecting the posterior segment of the study eye
|
[28]
|
RCT
|
116
|
n/a
|
3 years
|
Rate of recurrence of uveitis affecting the posterior segment of the study eye
|
Meloxicam
|
For relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis in patients 2 years of age or older
|
NSAID
|
2002
|
2005
|
RCT
|
n/a
|
≥2 years
|
12 weeks
|
ACR Pediatric 30
|
[29]
|
RCT
|
n/a
|
≥2 years
|
12 weeks
|
ACR Pediatric 30
|
Rilonacept
|
Treatment of cryopyrin-associated periodic syndromes
|
Interleukin inhibitor
|
2004
|
2008
|
RCT
|
47
|
n/a
|
24 weeks
|
CAPS symptom score
|
[30]
|
Adalimumab
|
Treatment of juvenile idiopathic arthritis
|
Tumor necrosis factor-alpha inhibitor
|
2005
|
2008
|
RCT
|
171
|
4 – 17 years
|
32 weeks
|
ACR Pediatric 30
|
[31]
|
OL
|
32
|
2 – ≤ 4 years or ≥ 4 years weighing < 15 kg
|
120 weeks
|
Safety
|
Rituximab
|
For the use in combination with glucocorticoids for the treatment of patients with Wegener’s granulomatosis and microscopic polyangiitis
|
Selective immunosuppressant
|
2006
|
2011
|
RCT
|
197
|
≥15 years
|
18 months
|
Birmingham Vasculitis Activity Score for Granulomatosis with Polyangiitis
|
[16]
|
Colchicine
|
Treatment of familial Mediterranean fever
|
Mitotic poison
|
2007
|
2009
|
Evidence for the efficacy was derived from the published literature.
|
[32]
|
RCT
|
15
|
n/a
|
n/a
|
n/a
| |
RCT
|
22
|
n/a
|
n/a
|
n/a
|
Canakinumab
|
Treatment of cryopyrin-associated periodic syndromes, in adults and children 4 years of age and older
|
Interleukin inhibitor
|
2007
|
2009
|
RCT
|
31
|
9 – 74 years
|
8 weeks
|
Minimal or better for physician’s assessment of disease activity, assessment of skin disease, and serum levels of C-Reactive Protein and Serum Amyloid A
|
[19]
|
OL
|
n/a
|
4 – 74 years
| |
n/a
|
Canakinumab
|
Treatment of active systemic juvenile idiopathic arthritis in patients aged 2 through 16 years
|
Interleukin inhibitor
|
2008
|
2013
|
RCT
|
84
|
mean 8.5 years (2 – 20)
|
4 weeks
|
Adapted ACR Pediatric 30 and absence of fever
|
[19]
|
RCT
|
177
|
mean 8.5 years (2 – 20)
|
n/a
|
ACR Pediatric 30
|
Difluprednate (ophthalmic solution)
|
Treatment of endogenous anterior uveitis
|
Glucocorticoid
|
2008
|
2012
|
RCT
|
110
|
n/a
|
2 weeks
|
Difference in anterior chamber cell grade
|
[33]
|
RCT
|
90
|
n/a
|
2 weeks
|
Difference in anterior chamber cell grade
|
Anakinra
|
Treatment of neonatal-onset multisystem inflammatory disease
|
Interleukin inhibitor
|
2010
|
2012
|
OL
|
43
|
0.7 – 46 years
|
60 months
|
disease-specific Diary Symptom Sum Score
|
[34]
|
Tocilizumab
|
Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age
|
Interleukin inhibitor
|
2012
|
2013
|
RCT
|
188
|
2 – 17 years
|
24 weeks
|
JIA ACR 30 flare
|
[20]
|